The US Food and Drug Administration (FDA) has accepted Intellia Therapeutics’ investigational new drug (IND) application to assess NTLA-5001 in a Phase 1/2a study for acute myeloid leukaemia (AML).

NTLA-5001 is the company’s first wholly-owned ex vivo CRISPR genome editing candidate for cancer treatment. The autologous T cell receptor (TCR)-T cell therapy is developed to target the Wilms’ Tumour (WT1) antigen to treat all genetic subtypes of AML.

The Phase 1/2a study will evaluate NTLA-5001 in adults with persistent or recurrent AML who have previously received first-line therapy. It will include up to 54 participants and will feature a dose escalation and expansion phase.

The study will particularly assess the safety, tolerability, cell kinetics and anti-tumour activity of a single dose of NTLA-5001 among the participants. Intellia plans to start patient screening by year-end.

Intellia president and CEO John Leonard said: “The FDA’s acceptance of our IND for NTLA-5001 is an important milestone in our pursuit of developing advanced cell therapies utilising Intellia’s proprietary engineering platform to treat patients with cancer.

“NTLA-5001 is our first wholly owned ex vivo candidate to enter the clinic, and we expect to initiate this first-in-human study in adults with AML by year-end.

“Our treatment strategy is to leverage CRISPR/Cas9 genome editing technology to create next-generation engineered immune cells with the potential to attack cancer cells more effectively and safely than previously developed cell therapies.”

A cancer of the blood and bone marrow, AML is the most common type of acute leukaemia in adults. The five-year overall survival rate for AML patients is currently less than 30%.

Earlier this month, BerGenBio concluded subject enrolment in a Phase Ib/II BGBC003 clinical trial of bemcentinib in AML and myelodysplastic syndrome (MDS) patients.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.